 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Stockwinners Market Radar for June 23, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
| ERI... | Hot Stocks19:17 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Eldorado Resorts (ERI) has agreed to merge with Caesars (CZR) in a cash and stock deal that values its peer at about $18B including debt, Reuters' Greg Roumeliotis reported, citing people familiar with the matter. The deal, which is expected to be announced on Monday, values Caesars at close to $13 a share, according to the sources. 2. FedEx (FDX) said an operational error prevented a Huawei package from being delivered to U.S., just weeks after the delivery company said an error led to the Chinese firm's packages being misdirected, Reuters' Kanishka Singh wrote. China's Global Times newspaper said in a tweet later the company is likely to be added to China's "unreliable entities list" due to the incident. 3. Passed unanimously last year, the California Consumer Privacy Act is the state's underappreciated attempt to regulate the collection and sale of personal data by Facebook (FB), Alphabet 's (GOOGL) Google, and other companies that rely on targeted advertising and the sale of consumer data to power their businesses, Eric Savitz wrote in this week's edition of Barron's. The law, which goes into effect on January 1, 2020, will force almost all companies to change the way they collect, handle, and share data on Californians, he noted, and the effects will spread everywhere. 4. In one of the biggest openings of all time for an animated movie, Pixar and Disney's (DIS) "Toy Story 4" won the North American box office over the weekend with $118M. Overseas, the movie launch to $120M for a $238M globally, a record for the genre. "Toy Story 4" received 98% on Rotten Tomatoes, while sporting an A CinemaScore. 5. Humana (HUM), Planet Fitness (PLNT), Marriott (MAR), Exxon Mobil (XOM), Chevron (CVX), Exelon (EXC), Prologis (PLD), NextEra (NEE) and Merlin Entertainments (MERLY) saw positive mentions in this week's edition of Barron's.
|
| RDY | Hot Stocks15:34 EDT Dr. Reddy's launches Vitamin K1 generic version equivalent in U.S. market - Dr. Reddy's announced the launch of Phytonadione Injectable Emulsion USP, 10 mg/ml Single-Dose Ampules, a therapeutic equivalent generic version of Vitamin K1 Injectable Emulsion USP, 10 mg/ml, approved by the U.S. Food and Drug Administration. The Vitamin K1 for Injectable Emulsion USP, 10 mg/ml brand and generic had combined U.S. sales of approximately $46.6M MAT for the most recent twelve months ending in April 2019 according to IQVIA Health. Dr. Reddy's Phytonadione Injectable Emulsion USP, 10 mg/ml Single-Dose Ampules is available in 1 mL Ampule containing 10 mg/mL of Phytonadione.
|
| MEIP | Hot Stocks14:46 EDT MEI Pharma presents updated data from ME-401 Phase 1b study - MEI Pharma announced that updated data presented in an oral presentation at ICML 2019 from a Phase 1b study of investigational ME-401, a selective oral inhibitor of PI3K delta, demonstrate an 83% overall response rate in patients with relapsed or refractory follicular lymphoma and r/r chronic lymphocytic leukemia or small lymphocytic lymphoma. Additionally, the data demonstrate: Overall response rates of 75% to 100% across all patient groups receiving ME-401. 100% overall response rate in all patients with CLL/SLL. A lower rate of delayed, grade 3 adverse events observed in patients dosed on the intermittent schedule. Durable responses in patients with FL and CLL/SLL across both CS and IS dosing groups. Median PFS not reached. MEI has initiated a global Phase 2 study to evaluate the efficacy, safety and tolerability of ME-401 as a single agent in patients with follicular lymphoma after failure of at least two prior systemic therapies including chemotherapy and an anti-CD20 antibody. The Phase 2 TIDAL study is intended to support an accelerated approval marketing application with the U.S. Food and Drug Administration.
|
